Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST: Carfilzomib, Thalidomide, and Dexamethasone in Relapsed AL Amyloidosis
NCT02545907Phase 2Completed
- Sponsor
- University College London
- Start
- Sep 2017
- Primary completion
- Sep 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in amyloid light chain amyloidosis, sponsored by University College London. Started Sep 2017; status: completed.
02
Drugs
carfilzomib
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02545907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02545907.